Ultrasonic method and device for wound treatment

Information

  • Patent Grant
  • 8235919
  • Patent Number
    8,235,919
  • Date Filed
    Monday, April 7, 2003
    21 years ago
  • Date Issued
    Tuesday, August 7, 2012
    12 years ago
Abstract
An apparatus and method are provided for generating ultrasonic energy from a non-contact distance from the surface of the wound; and delivering the generated ultrasonic energy to the wound through a gaseous medium. The generated ultrasonic energy has a significantly large amplitude such that the ultrasonic energy has an intensity capable of penetrating the wound tissue to a beneficial depth to provide a therapeutic effect for decreasing the healing time for the wound.
Description
FIELD OF THE INVENTION

The present invention relates to methods of using ultrasonic waves in wound treatment. More particularly, the present invention relates to a method of spraying a wound surface using ultrasonic waves for delivering drugs, killing bacteria, cleansing a surface and stimulating healthy tissue cells.


BACKGROUND OF THE INVENTION

Ultrasonic waves have been widely used in medical applications, including both diagnostics and therapy as well as many industrial applications. One diagnostic use of ultrasound waves includes using ultrasonic waves to detect underlying structures in an object or a human tissue. In this procedure, an ultrasonic transducer is placed in contact with the object or tissue via a coupling medium and high frequency (1-10 MHz) ultrasonic waves are directed into the tissue. Upon contact with various underlying structures, the waves are reflected back to a receiver adjacent the transducer. By comparison of the signals of the ultrasonic wave as sent with the reflected ultrasonic wave as received, an image of the underlying structure can be produced. This technique is particularly useful for identifying boundaries between components of tissue and can be used to detect irregular masses, tumors, and the like.


Two therapeutic medical uses of ultrasound waves include aerosol mist production and contact physiotherapy. Aerosol mist production makes use of a nebulizer or inhaler to produce an aerosol mist for creating a humid environment and delivering drugs to the lungs. Ultrasonic nebulizers operate by the passage of ultrasound waves of sufficient intensity through a liquid, the waves being directed at an air-liquid interface of the liquid at a point underneath or within the liquid. Liquid particles are ejected from the surface of the liquid into the surrounding air following the disintegration of capillary waves produced by the ultrasound energy. This technique can produce a very fine dense fog or mist. Aerosol mists produced by ultrasound are preferred over aerosol mists produced by other methods because a smaller particle size of aerosol can be obtained with the ultrasonic waves. One of the major shortcoming of inhalers and nebulizers is that the aerosol mist cannot be directed to a target area without an air stream, which decreases the efficiency of ultrasound. Ultrasonic sprayers such as those sold by Sonic and Materials Inc., Misonix Inc., Sono-Tek Inc. (see, for example, U.S. Pat. Nos. 4,153,201, 4,655,393, and 5,516,043) operate by passing liquid through a central orifice of an ultrasound instrument-tip. Major disadvantages of these sprayers include non-uniform particle size, heating of liquid flow, and less efficiency of ultrasound waves because of demolished end (radiation) surface configuration of the tip.


Contact physiotherapy applies ultrasonic waves directly to tissue in an attempt to produce a physical change in the tissue. In conventional ultrasound physiotherapy, an ultrasonic wave contacts the tissue via a coupling medium. Ultrasonic waves produced by the transducer travel through the coupling medium and into the tissue. The coupling medium is typically a bath of liquid, a jelly applied to the surface to be treated, or a water-filled balloon. Conventional techniques provide ultrasonic waves having an intensity of about 0.25 w/cm2 to 3 w/cm2 at a frequency of about 0.8 to 3 Megahertz. The treatment is applied to a skin surface for from about 1 to 30 minutes, two or three times a week. The coupling medium can provide a cooling effect which dissipates some of the energy produced by the ultrasonic transducer.


More importantly, a coupling medium or direct contact between the tissue and ultrasonic transducer is necessary to transmit the ultrasonic waves to the skin surface because ambient air is a relatively poor medium for the propagation of ultrasonic waves.


Several beneficial effects have been reported from contact ultrasound physiotherapy, such as, for example, the following: local improvement of the blood circulation, heating of the tissue, accelerated enzyme activity, muscle relaxation, pain reduction, and enhancement of natural healing processes. Despite these beneficial effects, current techniques of medical physiotherapy using ultrasonic waves are limited by the necessity of providing a direct contact interface between the ultrasonic transducer and the tissue to maintain an effective transmission of the ultrasonic waves from the transducer to the tissue.


The necessity of direct contact with or without a coupling medium makes current methods undesirable. Some tissue conditions may be accessible to contact ultrasound devices but would be impractical for contact ultrasound treatment. For example, fresh or open wounds resulting from trauma, burns or surgical interventions are not suitable for direct contact ultrasound treatment because of the structural nature of the open wound and the painful condition associated with those wounds. Moreover, conventional contact ultrasound may have a destructive effect on these types of open wounds due to the close proximity of an oscillating tip of an ultrasonic transducer relative to the already damaged tissue surface.


OBJECT OF THE INVENTION

It is an object of the invention to provide an improved method and device for treating wounds.


It is also an object of this invention to provide a method and device for treating wounds using ultrasonic waves.


It is a further object of the invention to provide a method and device for delivering drugs, killing bacteria, cleansing a surface, or stimulating healthy tissue cell growth.


It is a yet further object of the invention to treat a wound by spraying the surface of the wound with aerosol mist produced by ultrasonic waves.


These and other objects of the invention will become more apparent from the discussion below.


SUMMARY OF THE INVENTION

The present invention provides an apparatus and method for generating ultrasonic energy from a non-contact distance from the surface of the wound; and delivering the generated ultrasonic energy to the wound through a gaseous medium (“dry” approach), wherein the generated ultrasonic energy has an intensity capable of penetrating the wound tissue to a beneficial depth to provide a therapeutic effect for decreasing the healing time for the wound.


The present invention further relates to a method and device for spraying (“wet” approach) a wound surface to deliver drugs, kill bacteria, or cleanse a surface by non-contact application of an ultrasound transducer tip. The method applies ultrasonic waves to the wound without requiring direct or indirect (via a traditional coupling medium) contact between the ultrasonic wave transducer and the wound to be sprayed.


The method of the invention comprises producing a directed spray of liquid or powder particles produced by contact of the liquid or powder with a free end surface of an ultrasonic transducer. The ultrasonic waves cause the spray to project outwardly from the distal end surface of the ultrasonic transducer, and the particle spray is directed onto the wound. The particles of the spray provide a medium for propagation of the ultrasonic waves emanating from the distal end surface. According to the method of the present invention a directed particle spray created by low frequency ultrasound waves onto a wound, delivers drug, kills bacteria on the wound, increases blood flow, and removes dirt and other contaminants from the wound's surface (mechanical cleansing).


This method of drug delivery is particularly advantageous on tissues for which local topical application of a drug is desirable but contact with the tissue is to be avoided. Furthermore, the low frequency ultrasound waves used in the method energize the drug and cause penetration of the drug below the surface of the tissue. Finally, the bacteria killing method is effective when applied to the surface whether the liquid or powder sprayed is a drug (an antiseptic or antibiotic), oil, saline, distilled water, etc.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an ultrasonic wound treatment system according to the present invention;



FIG. 2 is a lateral schematic view of an ultrasonic sprayer according to the Present invention;



FIG. 3 is a partly cross-sectional view of an ultrasonic sprayer according to the present invention;



FIG. 4
a is a detailed view of the sprayer, illustrated in FIG. 3 for spraying liquid from a radiation surface;



FIG. 4
b is a detailed view of the sprayer illustrated in FIG. 3 for spraying liquid from a side (radial) surface;



FIG. 5 is a cross-sectional front view of a distal end of an ultrasonic transducer when liquid is delivered to the side or radiation surface of the transducer tip from 360° along its perimeter;



FIG. 6 is a variation of FIG. 4b illustrating the spraying effect by changing the angle between the ultrasound instrument and horizontal line from 0° to 90°;



FIGS. 7
a-7g are each a front cross-sectional view of an ultrasound tip configuration;



FIGS. 8
a-8i are each an enlarged side view of a different modification of a tip end shape of the ultrasonic sprayer according to the present invention;



FIGS. 9
a, 9b, and 9c represent cross-sectional, distal, and lateral views, respectively, of the top of an ultrasonic sprayer having a slot, groove, or thread;



FIG. 10 is a schematic representation of a method of delivery of ultrasonic energy delivered through a gaseous medium, accordance with another embodiment of the present invention; and



FIG. 11 is a plot of experimental results achieved upon delivering ultrasound energy substantially through a gaseous medium to a wound in accordance with the present invention.





DETAILED DESCRIPTION OF THE INVENTION

The device of the invention that produces a spray is characterized by means for first delivering the liquid to a lateral surface of an ultrasonic transducer tip adjacent to a free end surface such that the liquid is pulled to the free end surface by a vacuum (negative pressure) created by the ultrasound waves on the free end surface of the transducer tip. This effect can be achieved while the angle between the ultrasound instrument and the horizontal is modified up to 90°. (This acoustical effect of delivering liquid from radial side of a tip to the free end was discovered by the inventor of this invention and is called the “Babaev effect”.) This effect occurs when liquid is delivered to the radial surface of a transducer tip from 360° by perimeter as a top, side, bottom, etc.


For the above purpose the device must have a so-called nozzle from steel (nondisposable) or plastic (disposable) with a different design of valve. The nozzle allows delivery of liquid to the lateral surface of the transducer tip or directly to the distal side (radiation surface) of the ultrasound transducer to act as a sprayer or atomizer.


One of the major advantages of the invention is the uniformity of the spray particles generated. Because liquid or powder is sprayed from a solid radiation surface, there is substantial uniformity of particle size, about 90% or greater, preferably from about 90 to 96%. It is provided that the distal radiation surface is driven with constant frequency to create the spray. It is also provided that the frequency can be modulated during treatment and that the distal radiation surface is driven with a sinusoidal, rectangular, trapezoidal or triangular wave form.


The step of producing the spray can further include operating the transducer to produce ultrasonic waves having a frequency of from about 18 kHz to 10,000 MHz. Frequencies below 18 kHz, i.e., from about 1 to 18 kHz, can be used as well; however, this lower range is less desirable because this range of sound wave can be uncomfortable to the patient and operator (without ear protection or the like). Frequencies in the range of from about 30 to 100 kHz are preferred, and frequencies of about 40 kHz are most preferred.


The separation distance between the free end surface of the transducer and the surface or object to be sprayed should be a “non-contact” distance of at least 0.1 in. (2.5 mm). Preferably the separation distance is from about 0.1 in. (2.5 mm) to 20 in. (51 cm), more preferably from about 0.1 in. (2.5 mm) to 5 in. (12.7 cm). The liquid or powder to be sprayed can be any appropriate carrier such as water (regular or distilled), saline solution, or oil to be applied to tissue, such as a vegetable, peanut, or canola oil, optionally with a soluble pharmaceutical (e.g., an antibiotic), antiseptic, conditioner, surfactant, emollient, or other active ingredient. The pharmaceutical or the like is preferably present in a concentration sufficiently low to be soluble but high enough to be effective for the intended purpose.


It is within the scope of the invention that the liquid to be sprayed could comprise a mixture of two or more immiscible liquids or a heterogeneous mixture of a solution and small particles. It is also within the scope of the invention that the spray could comprise particles, such as powder.


The spray produced according to the invention is directed to the object, surface, or tissue to be sprayed for the time and frequency required to accomplish a particular purpose or treatment. It is believed that a minimum length of spray of at least one second will be required; however, the length or duration of the spray could be from about one second to as much as a minute or more, even 30 minutes. Numerous factors or circumstances, such as, for example, the area to be sprayed (e.g., the size of a wound), the volume rate of spray produced, the concentration of active ingredient, etc., will impact upon the duration and/or frequency of the spraying. Spraying could be required from one or more times daily to as little as two or three times a week or month.


According to the invention ultrasonic waves are applied to a wound without establishing contact, directly or indirectly, between the ultrasonic transducer and the wound. For example, surfaces of the human body especially suited for treatment with the method of the present invention include infected and inflammatory situations in open wounds, including trauma or gun shut wounds, fire and chemical burns.


In addition, the method of the present invention is particularly suited to directing a spray into orifices or other body crevices that are difficult to access.


Wound treatment according to the invention has several advantages. First, this method topically applies medicines such as liquid antibiotics to the wound surface without the need to contact infected, inflamed or painful tissue with an instrument. And second, a significant bactericidal effect occurs when a wound surface is sprayed using the method of the present invention.


Moreover, aside from the bactericidal effect and advantages of non-contact treatment, using the method of the present invention gave a significant reduction in volume used of liquid medicine used as compared with traditional methods for wound treatment. Similarly, this allows for precise dosage of the sprayed liquid to permit a user, such as a physician, to administer the desired volume of liquid at a desired rate and duration.


It has been found that the method of the present invention decreases healing times for inflammatory and purulent infected wounds that is from about 1.5 to 3 times faster than traditional methods. This effect results from a bactericidal, blood flow increasing and mechanical cleansing effect of the atomized spray particles, which have ultrasound energy due to the ultrasonic waves. The spray mechanically scrubs the surface of tissue to remove dirt, dead tissue, and purulent buildup on the tissue surface. The mentioned healing effect also results of energized and highly activated antibiotics, drug penetration into the tissue surface up to 0.5 mm in depth under influence of ultrasound waves.


Additionally, a combination of the low frequency ultrasonic waves and the sonicated medicines (highly activated by ultrasonic energy) destroy the surface bacteria to result in a higher disinfecting property of sonicated liquids as compared to ordinarily applied liquids.


The spray of the present method also stimulates healthy cell growth to aid in granulization and epithelization of the healing tissue.


Other applications of the invention can be directed to non-medical uses such as cleansing, sterilizing and coating surfaces of objects and food.


The method of the present invention offers an approach that may re-establish use of some traditional antibiotics and establish a method fighting bacteria without antibiotics when necessary. The effect of the method of the present invention in highly activating antibiotics may allow some traditional antibiotics to overcome bacteria which have become resistant to that antibiotic. Moreover, independent of the sonication effect of the antibiotics, the low frequency ultrasonic waves applied in the method of the present invention physically destroy bacteria. The combination of the highly activated antibiotics and of the low frequency ultrasonic waves in the method of the present invention produce a strong bactericidal effect not found in mere topical application or oral ingestion of antibiotics. This combined effect has been shown to significantly increase the healing of purulent infected wounds.


The present method also provides a system of non-contact drug delivery without use of a compression sprayer system. This simplifies the design of a non-contact drug delivery sprayer and reduces the weight of the sprayer. More importantly, not using compression to propel the atomized particles preserves the ultrasound energy carried by the spray particles.


Delivery of ultrasound energy in accordance with the present invention has been proven to destroy bacteria by action of the ultrasonic waves and by highly activated liquid medicines applied to the tissue.


The method of the present invention provides a method of compressionless no contact drug delivery.


The invention is better appreciated by making reference to the drawings. In FIG. 1, an ultrasonic treatment system 2 comprises an ultrasound wave generator 4, connected to an ultrasound transducer 6 by a cable 8. The wave generator 4, which is conventional, may have a front panel 10 with a power button 12, a timer 14, a control button 16, a display 18, and one or more jacks 20, for example, for connecting a footswitch. A nozzle 22 having a liquid reservoir 24 with a valve 26 is attached to the distal portion of transducer 6. Arrows 28 represent the direction of the spray produced.



FIG. 2 is a simplified representation of an ultrasonic device and spray according to the invention. Transducer 6 has a distal transducer tip or horn 30. Liquid from a liquid reservoir 32 flows through a valve 34 to a position adjacent the distal radiation surface 36 of a horn 30. Transducer 6 is attached to an ultrasound source via cable 8. A liquid mist is directed in the direction of arrows 38 to target tissue or surface 40 (wet approach).



FIG. 3 is an enlarged, partly cross-sectional view of a section of FIG. 1 illustrating a spray created by the device according to the method of the present invention. This device is a modification and implementation of a device disclosed in U.S. Pat. No. 5,076,266, which is incorporated herein by reference. As can be seen in more detail in FIG. 3, nozzle 22 surrounds ultrasound horn 30. Also, liquid reservoir 32 has a valve 34 positioned between reservoir 32 and the distal surface 36 of ultrasonic horn 30. A conical spray pattern of liquid droplets 42 is directed at a surface or tissue 44 of a target. This configuration is effective to spray liquid onto a surface and to deliver ultrasonic waves to that surface, such as, for example, the surface of a wound.


Valve 34 allows liquid to flow to distal tip 36 as drops or as a continuous flow through gap 46. Valve 34 may be located anywhere, including between reservoir 32 and horn 30. Mechanical movement of the horn 30 in the direction x-x causes liquid to flow to the distal end or radiation surface 36.



FIG. 4(
a) is a view of the ultrasonic sprayer as used in a method of the present invention for spraying liquid 48 directed to distal end (radiation surface) 36.



FIG. 4(
b) is a view of the basic spraying method from side (radial) surface of the tip based on the Babaev effect. In this case liquid or drug directed to the radiation surface 36 of ultrasound horn 30 becomes sonicated (ultrasonically energized), after being pulled forward by negative pressure (vacuum) created by ultrasound waves and sprays.


As shown in FIG. 5, liquid is delivered to the side or radiation surface 36 of transducer horn 30 from 360° along its perimeter as a top, side, bottom, etc.


In the embodiment of the invention shown in FIG. 6, a partial section of transducer horn 30 is elevated from the horizontal up to 90°. Due to the Babaev effect, liquid 48 still travels to radiation surface 36.


The ultrasound tip or horn may have a regular or irregular lateral cross-section, including circular, oval, elliptical, rectangular, trapezoidal, or a combination thereof. For example, FIGS. 7(a) to 7(g) are each a view of a cross-section of an ultrasound tip or horn. Also, the distal end shape of the ultrasound tip or horn longitudinal cross-section may vary and may be rectangular, elliptical, oval, spherical, conical, curved, stepped, with chamfer, etc. See, for example, FIGS. 8(a) to 8(n), which are each an enlarged view in section


of a different modification of a tip of the sprayer as used in the method of the present invention. The preferred shape is rectangular, because of radiation beams from ultrasound tip surface fully directed to the target (wound). With the spherical, elliptic and oval (FIG. 8(e)) form of shape end, radiation beams are focused at a focal point. However, with other forms of shape end, radiation beams are spread, thus partially reaching the target.


Radial side surface of the distal end of the tip may have a slot (groove) or thread for liquid to be directed to the radiation surface (FIG. 9).



FIGS. 9
a to 9c are each a view of a radial side surface of the distal end of the tip which has a slot (groove) 19 or thread 20 for liquid to be directed to the radiation surface.


In another embodiment, ultrasonic energy is delivered to the wound without the use of the spray, i.e., the ultrasonic energy is delivered through a medium other than a spray, including a gaseous medium, such as pure air, e.g., ambient air, where the ultrasound transducer 6 is positioned at a non-contact distance from the wound for providing a therapeutic and beneficial effect. The ultrasound waves, even without the use of a spray, destroy surface bacteria and stimulate health cell growth. This method of wound treatment is particularly advantageous on wounds for which contact with the wound should be avoided.


With reference to FIG. 10, an ultrasonic treatment system 2′ is shown including an ultrasound wave generator 4′ for generating ultrasound energy connected to an ultrasound transducer 6′ by a cable 8′. Transducer 6′ has a radiation surface 36′ from which the ultrasound energy is emitted and directed to wound 40′. The wave generator 4′, which is conventional, may have a front panel 10′ with a power button 12′, a timer 14′, a control button 16′, a display 18′, and one or more jacks 20′, for example, for connecting a footswitch. Arrows 100 represent the direction of ultrasound energy generated and directed toward wound 40′. Unlike the above embodiments, a liquid or powder is not contacted with the ultrasonic transducer for generating a spray and directing it to the wound 40′. The ultrasonic energy is delivered through a medium other than a spray, including a gaseous medium, such as pure air (“dry” approach).


In a preferred embodiment of the invention, wherein the ultrasonic energy is delivered to the wound 40′ through a gaseous medium, such as pure air, for achieving a therapeutic effect at the wound 40′, the frequency of the ultrasonic energy generated is selected to be a low frequency. By using a low frequency, a particular or predetermined amplitude for the generated ultrasonic energy is achieved, which is capable of being delivered to the wound with an intensity capable of providing a therapeutic effect to the wound 40′. Preferably, the amplitude achieved by the ultrasonic energy is at least 3 microns and preferably at least 10 micros. Preferably, the frequency used is in the range of 20 kHz-50 MHz, wherein a preferred range is 20-200 kHz, a more preferred range is 20-40 kHz and a most preferred value is 40 kHz, wherein most preferably the lower limit of the frequency used is outside of the human hearing range.


Furthermore, it is advantageous to use a radiation surface 36′ having a shape and size selected to achieve delivery of the ultrasonic energy to the wound where the delivered ultrasonic energy has an intensity capable of providing a therapeutic effect to the wound. Selection of the shape and size of the radiation surface 36′ in combination with selection of the frequency and amplitude of the ultrasonic energy used is advantageous in achieving delivery of the ultrasonic energy to the wound wherein the ultrasonic energy has an intensity capable of achieving a therapeutic effect to the wound. Preferably, the perimeter of the radiation surface 36′ is round and has a relatively large diameter. Actual selection of the diameter is dependent upon the frequency and amplitude selected. Furthermore, the shape of the radiation surface 36′ is selected from one of flat, concave, convex, and a combination thereof.


With respect to FIG. 11, results are shown of experimentation at Celleration Acoustic Laboratory, Eden Prairie, Minn. Ultrasonic energy having an intensity capable of providing a therapeutic effect was delivered through air (no spraying of liquid or powder) to a wound using an ultrasound transducer positioned at a non-contact distance from the surface of the wound, as shown by FIG. 10. The ultrasonic energy was generated at a frequency of 40 kHz and an amplitude of 61 microns. The transducer radiation surface was flat, rounded and had a diameter of 1 cm. Hydrophone model number PVDF-Z44-1000 and hydrophone amplifier model number A17db, both manufactured by ONDA Corporation, Sunnyvale, Calif., were employed, using an amplifier gain of 7.44. As shown, with the transducer positioned at a distance of between 2.5 mm and 38 mm from a wound, ultrasonic energy was delivered to the wound having an intensity capable of providing a therapeutic effect to the wound; the intensity being within the range of from 0.1 W/cm2 to 10 W/cm2.


The preceding specific embodiments are illustrative of the practice of the invention. It is to be understood, however, that other expedients known to those skilled in the art or disclosed herein, may be employed without departing from the spirit of the invention or the scope of the appended claims.

Claims
  • 1. A method for treating a wound comprising the steps of: generating ultrasonic energy having a frequency in the range of about 20 kHz to less than 50 kHz; anddelivering the generated ultrasonic energy to the wound through a gaseous medium from a non-contact distance from the surface of the wound in the absence of a coupling medium and without direct contact between an apparatus for generating and delivering ultrasonic energy and the wound and other patient tissue, wherein the generated ultrasonic energy has an intensity in the range of about 0.1 watts/cm2 to about 3 watts/cm2, and wherein the non-contact distance is at least 2.5 mm from the surface of the wound.
  • 2. The method according to claim 1, wherein the generating step includes generating the ultrasonic energy with a particular amplitude indicative of an intensity capable of penetrating the wound to a beneficial depth to provide a therapeutic effect for decreasing the healing time for the wound.
  • 3. The method according to claim 2, wherein the generating step further includes the step of generating the ultrasonic energy with a frequency capable of achieving the particular amplitude.
  • 4. The method according to claim 3, wherein the frequency is in the range of about 20 kHz to about 40 kHz.
  • 5. The method according to claim 2, wherein the particular amplitude is at least 3 microns.
  • 6. The method according to claim 2, wherein the particular amplitude is at least 10 microns.
  • 7. The method according to claim 2, wherein the particular amplitude is at least 35 microns.
  • 8. The method according to claim 7, wherein the particular amplitude is at least 61 microns.
  • 9. The method according to claim 1, further comprising the step of providing a transducer for delivering the ultrasonic energy, said transducer having a radiation surface with a surface area dimensioned for achieving delivery of the ultrasonic energy to the wound with an intensity capable of achieving a therapeutic effect.
  • 10. The method according to claim 9, wherein the radiation surface is positioned from about 2.5 mm to about 51 cm from the surface of the wound.
  • 11. The method according to claim 1, further comprising the step of providing a transducer for delivering the ultrasonic energy, said transducer having a radiation surface with a rounded perimeter for achieving delivery of the ultrasonic energy to the wound with an intensity capable of achieving a therapeutic effect.
  • 12. The method according to claim 1, further comprising the steps of: providing a transducer for delivering the ultrasonic energy having a radiation surface; andselecting at least one of a size of a surface area of the radiation surface, a shape of a peripheral boundary of the radiation surface, a frequency of the generated ultrasonic energy, and an amplitude of the generated ultrasonic energy for achieving delivery of ultrasonic energy to the wound with an intensity capable of achieving a therapeutic effect.
  • 13. The method of claim 1, further comprising the steps of: providing a transducer for delivering the ultrasonic energy having a radiation surface; andselecting a combination of a size of a surface area of the radiation surface, a shape of a peripheral boundary of the radiation surface, a shape of the curvature of the radiation surface selected from one of flat, concave, convex and a combination thereof, a frequency of the generated ultrasonic energy, and an amplitude of the generated ultrasonic energy for achieving a therapeutic effect.
  • 14. The method according to claim 1, wherein the generating step includes the steps of generating the ultrasonic energy with a constant or modulated frequency having a wave form selected from the group consisting of sinusoidal, rectangular, trapezoidal, and triangular wave forms.
  • 15. The method according to claim 1, wherein the method provides a therapeutic effect selected from the group consisting of increasing blood flow to the wound and stimulating cell growth.
  • 16. The method according to claim 1, wherein the gaseous medium includes a substantial expanse of a substantially purely gaseous medium.
  • 17. The method according to claim 1, wherein the non-contact distance is about 2.5 mm to 51 cm from the surface of the wound.
  • 18. The method according to claim 1, wherein the frequency is in the range of from about 30 to less than 50 kHz.
  • 19. The method according to claim 1, wherein the frequency is about 40 kHz.
  • 20. The method according to claim 1, wherein the wound is an open wound.
  • 21. A method for treating a wound comprising the steps of: generating ultrasonic energy having a particular amplitude and having a frequency in the range of about 20 kHz to less than 50 kHz; anddelivering the generated ultrasonic energy to the wound through a gaseous medium from a non-contact distance from the surface of the wound and without direct contact between an apparatus for generating and delivering ultrasonic energy and the wound and other patient tissue, wherein the gaseous medium does not include a liquid spray or other coupling medium, wherein the generated ultrasonic energy has an intensity in the range of about 0.1 watts/cm2 to about 3 watts/cm2, wherein the particular amplitude is indicative of said intensity, and wherein the non-contact distance is at least 2.5 mm from the surface of the wound.
  • 22. The method according to claim 21, wherein the wound is an open wound.
  • 23. A method for treating a wound comprising the steps of: generating ultrasonic energy having a frequency in the range of about 20 kHz to less than 50 kHz; anddelivering the generated ultrasonic energy to the wound through a gaseous medium from a non-contact distance from the surface of the wound and without direct contact between an apparatus for generating and delivering ultrasonic energy and the wound and other patient tissue, wherein the gaseous medium does not include a liquid spray or other coupling medium, wherein the generated ultrasonic energy has an intensity capable of penetrating the wound to a beneficial depth to provide a therapeutic effect for decreasing the healing time for the wound, wherein the frequency is capable of achieving a particular amplitude indicative of an intensity in the range of about 0.1 watts/cm2 to about 3 watts/cm2, and wherein the non-contact distance is at least 2.5 mm from the surface of the wound.
  • 24. A method for treating a wound comprising the steps of: generating ultrasonic energy having an amplitude of at least 3 microns and having a frequency in the range of about 20 kHz to less than 50 kHz; anddelivering the generated ultrasonic energy to the wound through a gaseous medium from a non-contact distance from the surface of the wound and without direct contact between an apparatus for generating and delivering ultrasonic energy and the wound and other patient tissue, wherein the gaseous medium does not include a liquid spray or other coupling medium, wherein the generated ultrasonic energy has an intensity in the range of about 0.1 watts/cm2 to about 3 watts/cm2, and wherein the non-contact distance is at least 2.5 mm from the surface of the wound.
  • 25. The method according to claim 24, wherein the ultrasonic energy has an amplitude of at least 10 microns.
Parent Case Info

This application is a Continuation-In-Part of U.S. application Ser. No. 09/669,312 filed on Sep. 25, 2000, by Eilaz Babaev, entitled: ULTRASONIC METHOD AND DEVICE FOR WOUND TREATMENT, the entire contents of which are hereby incorporated by reference.

US Referenced Citations (284)
Number Name Date Kind
2534046 Mau Dec 1950 A
2889852 Dunlap Jun 1959 A
3207181 Willis Sep 1965 A
3243122 Snaper Mar 1966 A
3275059 McCullough Sep 1966 A
3392916 Engstrom et al. Jul 1968 A
3433226 Boyd Mar 1969 A
3504887 Okerblom Apr 1970 A
3522801 Robinson Aug 1970 A
3561444 Boucher Feb 1971 A
3636947 Balamuth Jan 1972 A
3685634 Bergling Aug 1972 A
3685694 Ianelli Aug 1972 A
3765606 Moss et al. Oct 1973 A
3860173 Sata Jan 1975 A
3874372 Le Bon Apr 1975 A
3952918 Poitras et al. Apr 1976 A
4052004 Martin et al. Oct 1977 A
4085893 Durley, III Apr 1978 A
4153201 Berger et al. May 1979 A
4185502 Frank Jan 1980 A
4192294 Vasilevsky et al. Mar 1980 A
4251031 Martin et al. Feb 1981 A
4271705 Crostack Jun 1981 A
4294407 Reichl et al. Oct 1981 A
4301093 Eck Nov 1981 A
4301968 Berger et al. Nov 1981 A
4309989 Fahim Jan 1982 A
4319155 Nakai et al. Mar 1982 A
4331137 Sarui May 1982 A
4334531 Reichl et al. Jun 1982 A
4352459 Berger et al. Oct 1982 A
4414202 Silvetti Nov 1983 A
4428531 Martin Jan 1984 A
4466571 Muhlbauer Aug 1984 A
4530360 Duarte Jul 1985 A
4541564 Berger et al. Sep 1985 A
4551139 Plaas et al. Nov 1985 A
4582149 Slaughter, Jr. Apr 1986 A
4582654 Karnicky et al. Apr 1986 A
4619400 Van Der Burgt Oct 1986 A
4642581 Erickson Feb 1987 A
4655393 Berger Apr 1987 A
4659014 Soth et al. Apr 1987 A
4679551 Anthony Jul 1987 A
4726523 Kokubo et al. Feb 1988 A
4726525 Yonekawa et al. Feb 1988 A
4733820 Endo et al. Mar 1988 A
4756478 Endo et al. Jul 1988 A
4767402 Kost et al. Aug 1988 A
4783003 Hirabayashi et al. Nov 1988 A
4790479 Matsumoto et al. Dec 1988 A
4793339 Matsumoto et al. Dec 1988 A
4815661 Anthony Mar 1989 A
4818697 Liboff et al. Apr 1989 A
4850534 Takahashi et al. Jul 1989 A
4877989 Drews et al. Oct 1989 A
4883045 Theisz Nov 1989 A
4905671 Senge et al. Mar 1990 A
4930700 McKown Jun 1990 A
4941614 Ilott Jul 1990 A
4941618 Hildebrand et al. Jul 1990 A
4961885 Avrahami et al. Oct 1990 A
4982730 Lewis, Jr. Jan 1991 A
5002059 Crowley et al. Mar 1991 A
5013241 von Gutfeld et al. May 1991 A
5040537 Katakura Aug 1991 A
5045066 Scheuble et al. Sep 1991 A
5062795 Woog Nov 1991 A
5063922 Hakkinen Nov 1991 A
5067655 Farago et al. Nov 1991 A
5076266 Babeav Dec 1991 A
5104042 McKown Apr 1992 A
5115805 Bommannan et al. May 1992 A
5134993 van der Linden et al. Aug 1992 A
5143588 Liboff et al. Sep 1992 A
5152289 Viebach et al. Oct 1992 A
5163433 Kagawa et al. Nov 1992 A
5171215 Flanagan Dec 1992 A
5172692 Kulow et al. Dec 1992 A
5186162 Talish et al. Feb 1993 A
5197946 Tachibana Mar 1993 A
5211160 Talish et al. May 1993 A
5219401 Cathignol et al. Jun 1993 A
5231975 Bommannan et al. Aug 1993 A
5259384 Kaufman et al. Nov 1993 A
5269291 Carter Dec 1993 A
5309898 Kaufman et al. May 1994 A
5314441 Cusack et al. May 1994 A
5315998 Tachibana et al. May 1994 A
5316000 Chapelon et al. May 1994 A
5318014 Carter Jun 1994 A
5323769 Bommannan et al. Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5345940 Seward et al. Sep 1994 A
5347998 Hodson et al. Sep 1994 A
5362309 Carter Nov 1994 A
5374266 Kataoka et al. Dec 1994 A
5380411 Schlief Jan 1995 A
5386940 Berfield Feb 1995 A
5393296 Rattner Feb 1995 A
5431663 Carter Jul 1995 A
5437606 Tsukamoto Aug 1995 A
5456258 Kondo et al. Oct 1995 A
5515841 Robertson et al. May 1996 A
5515842 Ramseyer et al. May 1996 A
5516043 Manna et al. May 1996 A
5520166 Ritson et al. May 1996 A
5520612 Winder et al. May 1996 A
5523058 Umermura et al. Jun 1996 A
5527350 Grove et al. Jun 1996 A
5529572 Spector Jun 1996 A
5545124 Krause et al. Aug 1996 A
5547459 Kaufman et al. Aug 1996 A
5551416 Stimpson et al. Sep 1996 A
5554172 Horner et al. Sep 1996 A
5556372 Talish et al. Sep 1996 A
5573497 Chapelon Nov 1996 A
5611993 Babaev Mar 1997 A
5616140 Prescott Apr 1997 A
5618275 Bock Apr 1997 A
5626554 Ryaby et al. May 1997 A
5630828 Mawhirt et al. May 1997 A
5643179 Fujimoto Jul 1997 A
5656016 Ogden Aug 1997 A
5658323 Miller Aug 1997 A
5664570 Bishop Sep 1997 A
5688224 Forkey et al. Nov 1997 A
5699805 Seward et al. Dec 1997 A
5702360 Dieras et al. Dec 1997 A
5707402 Heim Jan 1998 A
5707403 Grove et al. Jan 1998 A
5725494 Brisken Mar 1998 A
5730705 Talish et al. Mar 1998 A
5735811 Brisken Apr 1998 A
5743863 Chapelon Apr 1998 A
5752924 Kaufman et al. May 1998 A
5762616 Talish Jun 1998 A
5785972 Tyler Jul 1998 A
5807285 Vaitekunas et al. Sep 1998 A
5835678 Li et al. Nov 1998 A
5843139 Goedeke et al. Dec 1998 A
5875976 Nelson et al. Mar 1999 A
5879314 Peterson et al. Mar 1999 A
5879364 Bromfield et al. Mar 1999 A
5882302 Driscoll, Jr. et al. Mar 1999 A
5894841 Voges Apr 1999 A
5895362 Elstrom et al. Apr 1999 A
5904659 Duarte et al. May 1999 A
5947921 Johnson et al. Sep 1999 A
5957882 Nita et al. Sep 1999 A
5960792 Lloyd et al. Oct 1999 A
5964223 Baran Oct 1999 A
5989245 Prescott Nov 1999 A
6001069 Tachibana et al. Dec 1999 A
6007499 Martin et al. Dec 1999 A
6014970 Irvi et al. Jan 2000 A
6024718 Chen et al. Feb 2000 A
6026808 Armer et al. Feb 2000 A
6027495 Miller Feb 2000 A
6036661 Schwarze et al. Mar 2000 A
6041253 Kost et al. Mar 2000 A
6061597 Rieman et al. May 2000 A
6076519 Johnson Jun 2000 A
6083159 Driscoll, Jr. et al. Jul 2000 A
6095141 Armer et al. Aug 2000 A
6098620 Lloyd et al. Aug 2000 A
6102298 Bush et al. Aug 2000 A
6104952 Tu et al. Aug 2000 A
6106547 Huei-Jung Aug 2000 A
6113558 Rosenschein et al. Sep 2000 A
6113570 Siegel et al. Sep 2000 A
RE36939 Tachibana et al. Oct 2000 E
6139320 Hahn Oct 2000 A
6158388 Wenstrand Dec 2000 A
6158431 Poole Dec 2000 A
6161536 Redmon et al. Dec 2000 A
6176839 DeLuis et al. Jan 2001 B1
6186963 Schwarze et al. Feb 2001 B1
6190315 Kost et al. Feb 2001 B1
6190336 Duarte et al. Feb 2001 B1
6206842 Tu et al. Mar 2001 B1
6206843 Iger et al. Mar 2001 B1
6231528 Kaufman et al. May 2001 B1
6234990 Rowe et al. May 2001 B1
6251099 Kollias et al. Jun 2001 B1
6254294 Muhar Jul 2001 B1
6273864 Duarte et al. Aug 2001 B1
6296630 Altman et al. Oct 2001 B1
6311573 Bhardwaj Nov 2001 B1
6314318 Petty Nov 2001 B1
6321109 Ben-Haim et al. Nov 2001 B2
6322527 Talish Nov 2001 B1
6325769 Klopotek Dec 2001 B1
6392327 Lewis et al. May 2002 B1
6450417 Gipson et al. Sep 2002 B1
6458109 Henley et al. Oct 2002 B1
6478754 Babaev Nov 2002 B1
6500133 Martin et al. Dec 2002 B2
6533484 Osei et al. Mar 2003 B1
6533803 Babaev Mar 2003 B2
6559365 Wilfer May 2003 B2
6569099 Babaev May 2003 B1
6583071 Weidman et al. Jun 2003 B1
6601581 Babaev Aug 2003 B1
6623444 Babaev Sep 2003 B2
6659365 Gipson et al. Dec 2003 B2
6663554 Babaev Dec 2003 B2
6666431 McCusker Dec 2003 B2
6723064 Babaev Apr 2004 B2
6732744 Olshavsky et al. May 2004 B2
6761729 Babaev Jul 2004 B2
6772967 Bontems Aug 2004 B1
6830556 Harmon et al. Dec 2004 B2
6916296 Soring et al. Jul 2005 B2
6960173 Babaev Nov 2005 B2
6964647 Babaev Nov 2005 B1
7025735 Soring et al. Apr 2006 B2
7316664 Kadziauskas et al. Jan 2008 B2
7431704 Babaev Oct 2008 B2
7572268 Babaev Aug 2009 B2
7662177 Babaev Feb 2010 B2
7713218 Babaev et al. May 2010 B2
7729779 Babaev Jun 2010 B2
7753285 Babaev Jul 2010 B2
7780095 Babaev Aug 2010 B2
7785277 Babaev et al. Aug 2010 B2
7785278 Babaev Aug 2010 B2
7830070 Babaev Nov 2010 B2
7914470 Babaev Mar 2011 B2
20020062093 Soring et al. May 2002 A1
20020080206 Lin Jun 2002 A1
20020138036 Babaev Sep 2002 A1
20020150539 Unger Oct 2002 A1
20020156400 Babaev Oct 2002 A1
20020177846 Mulier et al. Nov 2002 A1
20030023193 Soring et al. Jan 2003 A1
20030125660 Moutafis et al. Jul 2003 A1
20030144627 Woehr et al. Jul 2003 A1
20030153961 Babaev Aug 2003 A1
20030171701 Babaev Sep 2003 A1
20030195644 Borders et al. Oct 2003 A1
20030216687 Hwang Nov 2003 A1
20030236560 Babaev Dec 2003 A1
20040015105 Ito et al. Jan 2004 A1
20040028552 Bhardwaj et al. Feb 2004 A1
20040030254 Babaev Feb 2004 A1
20040034982 Wieber et al. Feb 2004 A1
20040055376 Thompson et al. Mar 2004 A1
20040068297 Palti Apr 2004 A1
20040073175 Jacobsen et al. Apr 2004 A1
20040076175 Patenaude Apr 2004 A1
20040091541 Unger May 2004 A1
20040186384 Babaev Sep 2004 A1
20050075587 Vago Apr 2005 A1
20050075620 Iger Apr 2005 A1
20060025716 Babaev Feb 2006 A1
20060058710 Babaev Mar 2006 A1
20070016110 Babaev et al. Jan 2007 A1
20070088245 Babaev et al. Apr 2007 A1
20070090205 Kunze et al. Apr 2007 A1
20070299369 Babaev Dec 2007 A1
20080051693 Babaev Feb 2008 A1
20080132888 Iida et al. Jun 2008 A1
20080177221 Millerd et al. Jul 2008 A1
20080183109 Babaev Jul 2008 A1
20080183200 Babaev Jul 2008 A1
20080214965 Peterson et al. Sep 2008 A1
20080243047 Babaev Oct 2008 A1
20080243048 Babaev Oct 2008 A1
20080306501 Babaev Dec 2008 A1
20090018491 Babaev Jan 2009 A1
20090018492 Babaev Jan 2009 A1
20090024076 Babaev Jan 2009 A1
20090043248 Peterson Feb 2009 A1
20090177122 Peterson Jul 2009 A1
20090177123 Peterson Jul 2009 A1
20090187136 Babaev Jul 2009 A1
20090200394 Babaev Aug 2009 A1
20090200396 Babaev Aug 2009 A1
20090222037 Babaev Sep 2009 A1
20090254005 Babaev Oct 2009 A1
20100022919 Peterson Jan 2010 A1
20100076349 Babaev Mar 2010 A1
Foreign Referenced Citations (34)
Number Date Country
2421798 Mar 2002 CA
2436812 Aug 2002 CA
1466445 Jan 2004 CN
0 020 844 Oct 1985 EP
0416106 Mar 1991 EP
0 437 155 Feb 1995 EP
0 657 226 Feb 1998 EP
0 619 104 Mar 2002 EP
1 564 009 Aug 2005 EP
2 099 710 Dec 1982 GB
2 101 500 Jan 1983 GB
3-73168 Mar 1991 JP
417844 Jan 1992 JP
9135908 May 1997 JP
2000-237275 Sep 2000 JP
878268 Nov 1981 RU
910157 Mar 1982 SU
1106485 Oct 1982 SU
1106485 Oct 1982 SU
1176968 Sep 1985 SU
1237261 Jun 1986 SU
1827239 May 1990 SU
1704847 Jan 1992 SU
WO 9406380 Mar 1994 WO
WO 9635383 Nov 1996 WO
9717933 May 1997 WO
0224150 Mar 2002 WO
WO0224150 Mar 2002 WO
WO 0228350 Apr 2002 WO
02055131 Jul 2002 WO
02060525 Aug 2002 WO
WO02060525 Aug 2002 WO
WO02095675 Nov 2002 WO
WO 2007002598 Jan 2007 WO
Related Publications (1)
Number Date Country
20030236560 A1 Dec 2003 US
Continuation in Parts (1)
Number Date Country
Parent 09669312 Sep 2000 US
Child 10409272 US